T1	Outcomes 697 783	better anatomic (six months) and visual (six and 24 months) outcomes and less hypotony
T2	Outcomes 896 932	decreased the likelihood of hypotony
T3	Outcomes 1100 1131	proliferative vitreoretinopathy
T4	Outcomes 1451 1469	equally effective.
